• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by SeaStar Medical Holding Corporation

    4/22/25 4:05:41 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care
    Get the next $ICU alert in real time by email
    S-8 1 2025_s-8_2022_omnibus_pl.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on April 22, 2025

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

     

    SeaStar Medical Holding Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

     

    Delaware

    001-39927

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. Employer
    Identification No.)

    3513 Brighton Blvd., Suite 410

    Denver, CO

    80216

    (Address of Principal Executive Offices)

    (Zip Code)

     

    Amended and Restated SeaStar Medical Holding Corporation 2022 Omnibus Incentive Plan

    (Full title of the plan)

     

    Eric Schlorff
    Chief Executive Officer
    3513 Brighton Blvd.

    Suite 410

    Denver, CO 80216

    (Name and address of agent for service)



    (844) 427-8100

    (Telephone number, including area code, of agent for service)

    With copies of all notices, orders, and communications to:

     

    Joshua Erekson

    Daniel Lyman

    Dorsey & Whitney LLP

    111 South Main Street, Suite 2100

    Salt Lake City, UT 84111

    (801) 933-7360

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (the “Registration Statement”), relating to the SeaStar Medical Holding Corporation 2022 Omnibus Incentive Plan (as amended, the “Incentive Plan”), is being filed pursuant to General Instruction E to Form S-8, for the purpose of registering: (i) an aggregate of 260,000 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”) (after giving effect to the reverse stock split referenced below), of SeaStar Medical Holding Corporation (the “Registrant”), reserved for issuance pursuant to an amendment to the Incentive Plan, which was approved by shareholders on June 4, 2024, (ii) an aggregate of 212,456 Shares reserved for issuance pursuant to the evergreen provision of the Incentive Plan, under which the share reserve is automatically increased annually in accordance with the terms of the Incentive Plan and (iii) pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), any additional shares of Common Stock that become issuable under the Incentive Plan by reason of any stock dividend, stock split, or other similar transaction.

     

    The Shares are securities of the same class and relate to the same employee benefit plan as the 50,800 shares of Common Stock (after giving effect to the reverse stock split referenced below) registered for issuance pursuant to the Registration Statement on Form S-8, File No. 333-270070, filed by the Registrant with the Securities and Exchange Commission (the “SEC”) on February 27, 2023 and the 47,200 shares of Common Stock (after giving effect to the reverse split referenced below) registered for issuance pursuant to the Registration Statement on Form S-8, File No. 333-276978, filed by the Registrant with the SEC on February 9, 2024 (collectively, the “Prior Registration Statements”). This Registration Statement is filed in accordance with General Instruction E to Form S-8. Accordingly, pursuant to General Instruction E, the Registrant hereby incorporates by reference herein the contents of the Prior Registration Statements and hereby deems such contents to be a part hereof, except as otherwise updated or modified by this Registration Statement.

     

    All share amounts referenced above and otherwise in this Registration Statement give effect to a 1-for-25 reverse stock split of the Common Stock, which was effected on June 7, 2024.

     

    PART II.

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the SEC pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are hereby incorporated by reference into this Registration Statement:

     

    (a)

    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2025;

     

     

    (b)

    The Registrant’s Current Reports on Form 8-K filed with the SEC on January 13, 2025 (except for Item 7.01 and any exhibits furnished under Item 7.01), January 31, 2025, February 3, 2025 (except for Item 7.01 and any exhibits furnished under Item 7.01), March 13, 2025, March 21, 2025; and March 28, 2025; and

     

     

    (c)

    The description of the Registrant’s Common Stock set forth in the Registrant’s registration statement on Form 8-A/A filed with the SEC on October 31, 2022, as updated by Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2025, and any amendment or report filed with the SEC for the purposes of updating such description.

     

    All other reports and other documents subsequently filed with the SEC by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of Exchange Act prior to the filing of a post-effective amendment to this registration statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold (other than those furnished pursuant to Item 2.02 or Item 7.01 of Form 8-K or other information deemed to have been “furnished” rather than “filed” in accordance with the SEC’s rules), shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such reports and documents.

     

     


     

    Any statement contained in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any other subsequently filed document that also is or is deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such prior statement. Any statement contained in this Registration Statement shall be deemed to be modified or superseded to the extent that a statement contained in a subsequently filed document that is or is deemed to be incorporated by reference in this Registration Statement modifies or supersedes such prior statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 8. Exhibits.

     

    A list of exhibits filed herewith is contained in the Exhibit Index that immediately precedes such exhibits and is incorporated herein by reference.

     

    EXHIBIT INDEX

     

    Exhibit
    No.

    Document

    4.1

    Third Amended and Restated Certificate of Incorporation of SeaStar Medical Holding Corporation, filed with the Secretary of State of Delaware on October 28, 2022 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on November 4, 2022).

    4.2

    Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of SeaStar Medical Holding Corporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 20, 2023).

    4.3

    Second Certificate of Amendment of Third Amended and Restated Certificate of Incorporation of SeaStar Medical Holding Corporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on June 7, 2024).

     

     

    4.4

    Third Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of SeaStar Medical Holding Corporation (incorporated by reference to Exhibit 3.4 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 27, 2025).

     

     

    4.5

    Second Amended and Restated Bylaws of SeaStar Medical Holding Corporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on April 18, 2024).

     

     

    5.1*

    Opinion of Dorsey & Whitney LLP.

    23.1*

    Consent of WithumSmith+Brown, PC independent registered public accounting firm.

    23.2*

    Consent of Dorsey & Whitney LLP (included in Exhibit 5.1 hereto).

    24.1*

    Power of Attorney (included in the signature page to this Registration Statement).

    99.1*+

    Amended and Restated SeaStar Medical Holding Corporation 2022 Omnibus Incentive Plan.

    107*

    Filing Fee Table.

    * Filed herewith

    + Denotes compensatory plan or arrangement

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Denver, State of Colorado on this 22nd day of April, 2025.

     

    SeaStar Medical Holding Corporation

    By:

    /s/ Eric Schlorff

    Name:

    Eric Schlorff

    Title:

    Chief Executive Officer

     

    POWER OF ATTORNEY

    Each of the undersigned, whose signature appears below, hereby constitutes and appoints Eric Schlorff as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments to this registration statement and to file the same with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing necessary or appropriate to be done with respect to this registration statement or any amendments hereto in the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue thereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities indicated below on April 22, 2025.

    Name

    Title

    Date

    /s/ Eric Schlorff

    Chief Executive Officer and Director

    (Principal Executive Officer)

    April 22, 2025

    Eric Schlorff

    /s/ David Green

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    April 22, 2025

    David Green

    /s/ Rick Barnett

    Chairman of the Board of Directors

    April 22, 2025

    Rick Barnett

    /s/ Kenneth Van Heel

    Director

    April 22, 2025

    Kenneth Van Heel

    /s/ Jennifer A. Baird

    Director

    April 22, 2025

    Jennifer A. Baird

    /s/ John Neuman

    Director

    April 22, 2025

    John Neuman

    /s/ Bernadette N. Vincent

    Director

    April 22, 2025

    Bernadette N. Vincent

     

     


    Get the next $ICU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ICU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/22/25 6:55:38 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Messinger Michael bought $5,098 worth of shares (14,500 units at $0.35), increasing direct ownership by 483% to 17,500 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/11/25 6:49:59 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Van Heel Kenneth bought $30,812 worth of shares (35,000 units at $0.88), increasing direct ownership by 243% to 49,400 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    8/28/25 5:28:58 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Van Heel Kenneth was granted 3,000 shares, increasing direct ownership by 61% to 7,940 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    2/10/26 4:58:51 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Neuman John was granted 3,000 shares, increasing direct ownership by 33% to 12,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    2/10/26 4:58:22 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Baird Jennifer A was granted 3,000 shares, increasing direct ownership by 83% to 6,620 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    2/10/26 4:57:09 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SeaStar Medical Holding Corporation

    SCHEDULE 13G/A - SeaStar Medical Holding Corp (0001831868) (Subject)

    2/13/26 4:43:46 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical Holding Corporation filed SEC Form 8-K: Other Events

    8-K - SeaStar Medical Holding Corp (0001831868) (Filer)

    1/20/26 4:03:22 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Amendment: SeaStar Medical Holding Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits

    8-K/A - SeaStar Medical Holding Corp (0001831868) (Filer)

    12/23/25 4:44:33 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

    Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company, announced today the publication of early post-approval clinical experience from the use of the QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the prestigious, peer-reviewed journal Pediatric Nephrology. The publication, co-authored by leading experts including Stuart Goldstein, Kelli Krallman, Meredith Harris, Rajit Basu, David Askenazi, Shina Menon, Ma

    2/9/26 8:20:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference

    DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on Thursday, February 5th at 11:30 am Eastern Time. Interested investors and guests of SeaStar Medical can register and view the live investor presentations here: Virtual Equity Conference Registration. A replay of the SeaStar Medical presentation will be available on Monday, February 9th aft

    1/29/26 8:25:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical Announces 2026 Milestones

    Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical's first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion market – through completion of enrollment of the NEUTRALIZE-AKI pivotal trial and initiation of the PMA process Progress the clinical development of the SCD therapy in patients with severe heart failure Leverage rapid pathways to commercialization of the SCD therapy through additional FDA Humanitarian Use and Breakthrough Device Designations DENVER, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company fo

    1/7/26 8:13:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    Financials

    Live finance-specific insights

    View All

    SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates

    Business highlights include: Three new top-rated children's hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI)Commercial use of QUELIMMUNE therapy demonstrates positive survival results as reported from the QUELIMMUNE SAVE Surveillance RegistryNew clinical sites added to expand adult NEUTRALIZE-AKI pivotal trial enrollmentStrengthened the balance sheet, raising $12.4 million to fund future operationsWebcast call today at 4:30 p.m. Eastern Time DENVER, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure

    11/13/25 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025

    DENVER, Nov. 05, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its third quarter financial results after market close on Thursday, November 13, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Thursday, November 13, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Dial-in number:To join the conference call via phone, please pre-register online here to receive a telephone number

    11/5/25 10:03:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

    DENVER, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, August 13, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, August 13, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Conference ID:2078693Dial-in numbers:1 (800) 715-9871 within the U.S.1 (646) 307-1963 from outside the U.S.

    8/7/25 10:00:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    Leadership Updates

    Live Leadership Updates

    View All

    SeaStar Medical Announces Appointment of Michael Messinger as CFO

    DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a seasoned healthcare executive with over 25 years of industry experience, has joined SeaStar Medical as Chief Financial Officer. "Mike brings to SeaStar Medical a breadth of financial expertise, operational discipline, and strategic healthcare experience that will be invaluable as we grow our commercial operations and prepare for additional commercial opportunities for our SCD therapy," stated Eric Schlorff, CE

    11/17/25 8:43:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SeaStar Medical Holding Corporation

    SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

    11/14/24 5:35:52 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care